Quest for the right Drug

|

צפטריאקסון - תרימה 1 גרם CEFTRIAXONE - TRIMA 1G (CEFTRIAXONE AS SODIUM)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-שרירי, תוך-ורידי : I.M, I.V

צורת מינון:

אבקה להמסה להזרקהאינפוזיה : POWDER FOR SOLUTION FOR INJ/INF

Adverse reactions : תופעות לוואי

4.8 Undesirable effects

The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.
Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials.

The following convention has been used for the classification of frequency: - Very common (≥ 1/10);
- Common (≥ 1/100 - < 1/10);
- Uncommon (≥ 1/1000 - < 1/100);
- Rare (≥ 1/10000 - < 1/1000);
- Not known (cannot be estimated from the available data);


System Organ Class          Common             Uncommon                         Rare              Not Knowna Infections and                            Genital fungal infection Pseudomembranous colitisb Superinfectionb infestations
Blood and lymphatic    Eosinophilia       Granulocytopenia                                   Haemolytic anaemiab system disorders       Leucopenia         Anaemia                                            Agranulocytosis Thrombocytopenia   Coagulopathy
Immune system                                                                                Anaphylactic shock disorders                                                                                    Anaphylactic reaction Anaphylactoid reaction
Hypersensitivityb
Jarisch-Herxheimer reactionb
Nervous system                            Headache                   Encephalopathy          Convulsion disorders                                 Dizziness
Ear and                                                                                      Vertigo labyrinth disorders
Respiratory,                                                         Bronchospasm thoracic and mediastinal disorders
Gastrointestinal       Diarrhoeab         Nausea                                             PancreatitisbStomatitis disorders              Loose stools       Vomiting                                           Glossitis Hepatobiliary          Hepatic enzyme                                                        Gall bladder disorders              increased                                                             precipitationb Kernicterus
Hepatitisc
Hepatitis cholestaticb,c
Skin and               Rash               Pruritus                   Urticaria               Stevens Johnson Syndromeb subcutaneous                                                                                 Toxic epidermal necrolysisb tissue disorders                                                                             Erythema multiform Acute generalised exanthematous
Pustulosis
Drug reaction with eosinophilia and systemic symptoms
(DRESS)b
Renal and                                                            Haematuria              Oliguria urinary                                                              Glycosuria              Renal precipitation(reversible) disorders
General                                   Phlebitis Injection site   Oedema disorders and                             pain                       Chills administration                            Pyrexia
site conditions

Investigations                           Blood creatinine                            Coombs test false positiveb increased                                   Galactosaemia test false positiveb
Non enzymatic methods for glucose determination false positiveb

 a
Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency, which is therefore categorised as not known.
b
See section 4.4 c
Usually reversible upon discontinuation of ceftriaxone


Infections and infestations
Reports of diarrhoea following the use of ceftriaxone may be associated with Clostridium difficile. Appropriate fluid and electrolyte management should be instituted (see section 4.4).

Ceftriaxone-calcium salt precipitation
Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium.

Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem.
The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).

Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. ≥ 80 mg/kg/day or total doses exceeding 10 grams) and who have other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).

Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30% in some studies. The incidence appears to be lower with slow infusion (20-30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il.
You can also report by email to: safety@trima.co.il.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום

רישום

169 65 36258 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

07.11.22 - עלון לרופא 15.12.23 - עלון לרופא

עלון מידע לצרכן

לתרופה במאגר משרד הבריאות

צפטריאקסון - תרימה 1 גרם

קישורים נוספים

RxList WebMD Drugs.com